Integration of Flow Cytometry and Single-Cell RNA Sequencing Analysis to Explore the Fibroblast Subpopulations in Keloid that Correlate with Recurrence
Restricted accessResearch articleFirst published online June, 2026
Integration of Flow Cytometry and Single-Cell RNA Sequencing Analysis to Explore the Fibroblast Subpopulations in Keloid that Correlate with Recurrence
Fibroblasts (FBs) are the cytological basis of keloid (KD) formation. This study aimed to identify the key pathogenic target cell subpopulation involved in KD recurrence.
Approach:
Single-cell RNA sequencing data were retrieved from public databases, revealing distinct gene expression patterns in FB subpopulations. Flow cytometry (FCM) was used to identify the surface molecular phenotypes of FBs that affect KD recurrence. Simultaneously, logistic regression analysis was performed to assess the predictive value of changes in FB subpopulation percentages for clinical KD recurrence.
Results:
The percentage of keloid fibroblasts was significantly greater than that in normal tissues. Through further clustering analysis of the FB population, we obtained four subpopulations, FB1–FB4, in which the percentages of FB1 subpopulation were increased, and functional enrichment analysis suggested that the FB1 subpopulation may play a greater role in extracellular matrix collagen oversynthesis in KD. In addition, the gene expression of CD26 (DPP4), CD117 (c-KIT), and CD34 in the FB1 subpopulation was significantly higher than that in FB2–4 subpopulations. Moreover, the percentage of CD26+/CD117+/CD34+ cell subpopulations in the FCM data of patients with KD recurrence was significantly increased. Regression analysis confirmed that the CD26+/CD117+/CD34+ FB subpopulation was a risk factor for relapse.
Innovation:
We demonstrated that the molecular phenotypic and functional heterogeneity of FBs influences KD recurrence.
Conclusion:
We identified key pathogenic FB subpopulations that may affect KD development, which can be used as potential markers to predict recurrence and provide potential target cell populations for future clinical treatment.
LimandjajaGC, NiessenFB, ScheperRJ, et al.The keloid disorder: Heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol, 2020; 8:360.
2.
LeeHJ, JangYJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci, 2018; 19(3).
3.
CoentroJQ, PuglieseE, HanleyG, et al.Current and upcoming therapies to modulate skin scarring and fibrosis. Adv Drug Deliv Rev, 2019; 146:37–59.
4.
TalbottHE, MascharakS, GriffinM, et al.Wound healing, fibroblast heterogeneity, and fibrosis. Cell Stem Cell, 2022; 29(8):1161–1180.
5.
ChenK, HennD, JanuszykM, et al.Disrupting mechanotransduction decreases fibrosis and contracture in split-thickness skin grafting. Sci Transl Med, 2022; 14(645):eabj9152.
6.
Baker FrostD, SavchenkoA, TakamuraN, et al.A positive feedback loop exists between estradiol and IL-6 and contributes to dermal fibrosis. Int J Mol Sci, 2024; 25(13).
7.
ZhangC, JinH, KangY, et al.IL-17A-neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5/CXCR2 axis. Faseb J, 2024; 38(19):e70096.
8.
Gawronska-KozakB, Machcinska-ZielinskaS, WalendzikK, et al.Hypoxia and Foxn1 alter the proteomic signature of dermal fibroblasts to redirect scarless wound healing to scar-forming skin wound healing in Foxn1(-/-) mice. BMC Biol, 2024; 22(1):193.
9.
SuL, HanJ. Non-coding RNAs in hypertrophic scars and keloids: Current research and clinical relevance: A review. Int J Biol Macromol, 2024; 256(Pt 1):128334.
10.
TziotziosC, ProfyrisC, SterlingJ. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part II. Strategies to reduce scar formation after dermatologic procedures. J Am Acad Dermatol, 2012; 66(1):13–24; quiz 5-6.
11.
GriffinMF, desJardins-ParkHE, MascharakS, et al.Understanding the impact of fibroblast heterogeneity on skin fibrosis. Dis Model Mech, 2020; 13(6).
12.
AndrewsJP, MarttalaJ, MacarakE, et al.Keloids: The paradigm of skin fibrosis-Pathomechanisms and treatment. Matrix Biol, 2016; 51:37–46.
13.
QianH, ZhangL, WangC, et al.Chlorpheniramine maleate exerts an anti-keloid activity by regulation of IL-6/JAK1/STAT3 signaling pathway. Int Immunopharmacol, 2025; 148:114181.
14.
ZhouH, YangP, ZhangT, et al.The role of apoptosis, immunogenic cell death, and macrophage polarization in carbon ion radiotherapy for keloids: Targeting the TGF-β1/SMADs signaling pathway. Biochim Biophys Acta Mol Basis Dis, 2025; 1871(1):167499.
15.
DriskellRR, LichtenbergerBM, HosteE, et al.Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature, 2013; 504(7479):277–281.
16.
RognoniE, WattFM. Skin cell heterogeneity in development, wound healing, and cancer. Trends Cell Biol, 2018; 28(9):709–722.
17.
LynchMD, WattFM. Fibroblast heterogeneity: Implications for human disease. J Clin Invest, 2018; 128(1):26–35.
18.
MizoguchiF, SlowikowskiK, WeiK, et al.Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun, 2018; 9(1):789.
19.
SuppDM, HahnJM, GlaserK, et al.Deep and superficial keloid fibroblasts contribute differentially to tissue phenotype in a novel in vivo model of keloid scar. Plast Reconstr Surg, 2012; 129(6):1259–1271.
20.
TabibT, MorseC, WangT, et al.SFRP2/DPP4 and FMO1/LSP1 define major fibroblast populations in human skin. J Invest Dermatol, 2018; 138(4):802–810.
DengCC, HuYF, ZhuDH, et al.Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases. Nat Commun, 2021; 12(1):3709.
23.
Solé-BoldoL, RaddatzG, SchützS, et al.Single-cell transcriptomes of the human skin reveal age-related loss of fibroblast priming. Commun Biol, 2020; 3(1):188.
24.
LeavittT, HuMS, MarshallCD, et al.Scarless wound healing: Finding the right cells and signals. Cell Tissue Res, 2016; 365(3):483–493.
25.
ShimJ, OhSJ, YeoE, et al.Integrated analysis of single-cell and spatial transcriptomics in keloids: Highlights on Fibrovascular interactions in keloid pathogenesis. J Invest Dermatol, 2022; 142(8):2128–2139.e11.
26.
DirederM, WielscherM, WeissT, et al.The transcriptional profile of keloidal Schwann cells. Exp Mol Med, 2022; 54(11):1886–1900.
27.
ZhangX, LanY, XuJ, et al.CellMarker: A manually curated resource of cell markers in human and mouse. Nucleic Acids Res, 2019; 47(D1):D721–D728.
28.
AranD, LooneyAP, LiuL, et al.Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol, 2019; 20(2):163–172.
29.
WuT, HuE, XuS, et al.clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb), 2021; 2(3):100141.
30.
HänzelmannS, CasteloR, GuinneyJ. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 2013; 14:7.
31.
YangK, ShiM, LiS, et al.The efficacy of sequentially comprehensive treatment based on surgery in the treatment of keloids: A retrospective study. Front Med (Lausanne), 2024; 11:1492407.
32.
KimJS, LeeGY, ChaeSW, et al.Pediatric keloids: A retrospective, single-institution cohort analysis in Korea. Pediatr Dermatol, 2025; 42(1):54–60.
33.
LiuX, ChenW, ZengQ, et al.Single-Cell RNA-Sequencing reveals lineage-specific regulatory changes of fibroblasts and vascular endothelial cells in keloids. J Invest Dermatol, 2022; 142(1):124–135.e11.
34.
IchiokaS, AndoT, ShibataM, et al.Oxygen consumption of keloids and hypertrophic scars. Ann Plast Surg, 2008; 60(2):194–197.
35.
VincentAS, PhanTT, MukhopadhyayA, et al.Human skin keloid fibroblasts display bioenergetics of cancer cells. J Invest Dermatol, 2008; 128(3):702–709.
36.
ZhangJ, HaoL, LiS, et al.mTOR/HIF-1α pathway-mediated glucose reprogramming and macrophage polarization by Sini decoction plus ginseng soup in ALF. Phytomedicine, 2025; 137:156374.
37.
TóthA, LenteG, CsikiDM, et al.Activation of PERK/eIF2α/ATF4/CHOP branch of endoplasmic reticulum stress response and cooperation between HIF-1α and ATF4 promotes Daprodustat-induced vascular calcification. Front Pharmacol, 2024; 15:1399248.
38.
YanK, ZhangRK, WangJX, et al.Using network pharmacology and molecular docking technology, proteomics and experiments were used to verify the effect of Yigu Decoction (YGD) on the expression of key genes in osteoporotic mice. Ann Med, 2025; 57(1):2449225.
39.
WongVW, RustadKC, AkaishiS, et al.Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med, 2011; 18(1):148–152.
40.
DuscherD, MaanZN, WongVW, et al.Mechanotransduction and fibrosis. J Biomech, 2014; 47(9):1997–2005.
41.
XiongJ, BalciogluHE, DanenEH. Integrin signaling in control of tumor growth and progression. Int J Biochem Cell Biol, 2013; 45(5):1012–1015.
42.
Jamal-HanjaniM, QuezadaSA, LarkinJ, et al.Translational implications of tumor heterogeneity. Clin Cancer Res, 2015; 21(6):1258–1266.
43.
WuD, WangDC, ChengY, et al.Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Semin Cancer Biol, 2017; 42:13–19.
44.
XiaY, WangY, XiaoY, et al.Identification of a diagnostic signature and immune cell infiltration characteristics in keloids. Front Mol Biosci, 2022; 9:879461.
45.
WangL, TangL, ZhouL, et al.Identification of CGNL1 as a diagnostic marker in fibroblasts of diabetic foot ulcers: Insights from single cell RNA sequencing and bulk sequencing data. Int J Immunopathol Pharmacol, 2024; 38:3946320241265945.
46.
LiJ, XiaY, KongS, et al.Single-cell RNA-seq reveals actinic keratosis-specific keratinocyte subgroups and their crosstalk with secretory-papillary fibroblasts. J Eur Acad Dermatol Venereol, 2023; 37(11):2273–2283.
47.
XinY, MinP, XuH, et al.CD26 upregulates proliferation and invasion in keloid fibroblasts through an IGF-1-induced PI3K/AKT/mTOR pathway. Burns Trauma, 2020; 8:tkaa025.
48.
GarbuzenkoE, NaglerA, PickholtzD, et al.Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: A direct role for mast cells in skin fibrosis. Clin Exp Allergy, 2002; 32(2):237–246.
49.
MukhopadhyayA, DoDV, OngCT, et al.The role of stem cell factor and c-KIT in keloid pathogenesis: Do tyrosine kinase inhibitors have a potential therapeutic role? Br J Dermatol, 2011; 164(2):372–386.
50.
AbuSamraDB, AleisaFA, Al-AmoodiAS, et al.Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44. Blood Adv, 2017; 1(27):2799–2816.
51.
Díaz-FloresL, GutiérrezR, González-GómezM, et al.CD34+ Stromal Cells/Telocytes as a Source of Cancer-Associated Fibroblasts (CAFs) in invasive lobular carcinoma of the breast. Int J Mol Sci, 2021; 22(7).
52.
XinY, WangX, ZhuM, et al.Expansion of CD26 positive fibroblast population promotes keloid progression. Exp Cell Res, 2017; 356(1):104–113.
53.
IqbalSA, SidgwickGP, BayatA. Identification of fibrocytes from mesenchymal stem cells in keloid tissue: A potential source of abnormal fibroblasts in keloid scarring. Arch Dermatol Res, 2012; 304(8):665–671.
54.
QuM, SongN, ChaiG, et al.Pathological niche environment transforms dermal stem cells to keloid stem cells: A hypothesis of keloid formation and development. Med Hypotheses, 2013; 81(5):807–812.
55.
WangCH, ShanMJ, LiuH, et al.Hyperbaric oxygen treatment on keloid tumor immune gene expression. Chin Med J (Engl), 2021; 134(18):2205–2213.
56.
KurachiI, KuritaE, TakushimaA, et al.Human CD206+ macrophages show antifibrotic effects on human fibroblasts through an IL-6-Dependent mechanism in vitro. Plast Reconstr Surg, 2021; 147(2):231e–239e.
57.
TosaM, GhazizadehM, ShimizuH, et al.Global gene expression analysis of keloid fibroblasts in response to electron beam irradiation reveals the involvement of interleukin-6 pathway. J Invest Dermatol, 2005; 124(4):704–713.
58.
ZhangM, ChenH, QianH, et al.Characterization of the skin keloid microenvironment. Cell Commun Signal, 2023; 21(1):207.
59.
HahnJM, CombsKA, PhillipsCM, et al.CYP24A1 is overexpressed in keloid keratinocytes and its inhibition alters profibrotic gene expression. Burns Trauma, 2025; 13:tkae063.
60.
XiaY, WangY, ShanM, et al.Decoding the molecular landscape of keloids: New insights from single-cell transcriptomics. Burns Trauma, 2023; 11:tkad017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
